Quick Answer
Amneal Pharmaceuticals, Inc. reported Long-Term Debt of $2.57 billion for fiscal year 2025.
Amneal Pharmaceuticals, Inc. Long-Term Debt — Annual History
| Fiscal Year | Long-Term Debt | YoY Change |
|---|---|---|
| 2025 | $2.57B | +18.7% |
| 2024 | $2.16B | -9.4% |
| 2023 | $2.39B | -7.9% |
| 2022 | $2.59B | -3.3% |
| 2021 | $2.68B | -2.0% |
| 2020 | $2.74B | +4.8% |
| 2019 | $2.61B | -0.8% |
| 2018 | $2.63B | +94.1% |
| 2017 | $1.36B | — |
Quarterly Long-Term Debt
| Quarter Ending | Long-Term Debt | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $2.57B | +18.3% | +19.6% |
| June 30, 2025 | $2.15B | -1.4% | -0.4% |
| March 31, 2025 | $2.15B | -9.4% | -0.4% |
| December 31, 2024 | $2.16B | -9.4% | -0.4% |
| September 30, 2024 | $2.17B | -14.6% | -0.4% |
| June 30, 2024 | $2.18B | -14.6% | -8.4% |
| March 31, 2024 | $2.38B | -7.2% | -0.3% |
| December 31, 2023 | $2.39B | -7.9% | -6.1% |
- Amneal Pharmaceuticals, Inc. showed an increase of +18.7% in Long-Term Debt compared to the prior fiscal year.
- Over the 2017–2025 period, Amneal Pharmaceuticals, Inc.’s long-term debt has grown by 89.3% (from $1.36 billion to $2.57 billion).
- The most recent figure is from Amneal Pharmaceuticals, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 27, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: